Wednesday, February 16, 2022
8:53 AM EST – BioVaxys Technology Corp : Announces complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein. Studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 receptor. The finding suggests that the Company’s haptenized SARS-CoV-2 spike protein vaccine may not lead to the unusual but serious myocarditis observed with mRNA vaccines, suggesting superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines. BioVaxys Technology Corp (C.BIOV) shares were unchanged at 0.17.
Stocks in Play: BioVaxys Technology Corp, Wed, 16 Feb 2022 09:12:07 EST